Approaches to the detection of ovarian cancer

References

• Engholm GFJ, Christensen N, Kejs AMT, Johannesen TB, Khan S, Leinonen MK, Milter MC, Ólafsdóttir E, Petersen T, Trykker H, Storm HH. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries. 16.12.2015; Version 7.2. Available from: http://www-dep.iarc.fr/NORDCAN.htm.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Annual Report 2014–2015. Danish Gynecological Cancer Database. Nationwide clinical database for cancer of the ovaries, uterus and cervix. København: Lægeforeningens forlag 2015; pp 1–69. (Online). Available from: http://dgcg.dk/images/rsrapport_DGCD_2014-15.pdf. 2015
   Google Scholar
• Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99:447–61.
   PubMed Web of Science ®Google Scholar
• Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006;16:11–7.
   PubMed Web of Science ®Google Scholar
• Fagö-Olsen CL, Høgdall C, Kehlet H, Christensen IJ, Ottesen B. Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta Obstet Gynecol Scand 2011;90:273–9.
   PubMed Web of Science ®Google Scholar
• Hansen RP, Vedsted P, Sokolowski I, Søndergaard J, Olesen F. Time intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients. BMC Health Serv Res 2011;11:284
   PubMed Web of Science ®Google Scholar
• Jacobs I, Oram D. Screening for ovarian cancer. Biomed Pharmacother 1988;42:589–96.
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355–66.
   PubMed Web of Science ®Google Scholar
• Retningslinier for visitation, diagnostik og kontrol af epithelial ovarie-, tuba- og primær peritonealcancer samt borderlinetumorer. [Guidelines for triage, diagnosis and control of epithelial ovarian, tuba- and primary peritoneal cancer and borderline tumors]. DGCG 2016. Available from: http://www.dgcg.dk/.
   Google Scholar
• Høgdall CK, Mogensen O, Tabor A, Mogensen B, Jakobsen AK, Norgaard Pedersen B, Larsen SO, Clemmensen I. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol Oncol 1995;56:22–8.
   PubMed Web of Science ®Google Scholar
• Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer:updated guidelines from the European group on tumor markers. Int J Gynecol Cancer 2016;26:43–51.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883–7.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M. CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679–91.
   PubMed Web of Science ®Google Scholar
• Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267–77.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922–9.
   PubMedGoogle Scholar
• Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402–8.
   PubMed Web of Science ®Google Scholar
• Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695–700.
   PubMed Web of Science ®Google Scholar
• Karlsen NS, Karlsen MA, Høgdall CK, Høgdall EV. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. Cancer Epidemiol Biomarkers Prev 2014;23:2285–95.
   PubMed Web of Science ®Google Scholar
• Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr., Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40–6.
   PubMed Web of Science ®Google Scholar
• Karlsen MA1, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012;127:379–83.
   PubMed Web of Science ®Google Scholar
• Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer 2012;22:24–6.
   PubMed Web of Science ®Google Scholar
• Karlsen MA, Høgdall EV, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, Chovanec J, Lok CA, Stiekema A, Mutz-Dehbalaie I, Rosenthal AN, Moore EK, Schodin BA, Sumpaico WW, Sundfeldt K, Kristjansdottir B, Zapardiel I, Høgdall CK. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer: an international multicenter study in women with an ovarian mass. Gynecol Oncol 2015;138:640–6.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Derchain SF, Pitta DR, De Angelo Andrade LA, Sarian LO. Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): two equivalent ways to differentiate malignant from benign ovarian tumors before surgery? Gynecol Oncol 2016;140:481–5.
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945–56.
   PubMed Web of Science ®Google Scholar